Fischer 344 Rat: A Preclinical Model for ...
Type de document :
Compte-rendu et recension critique d'ouvrage
Titre :
Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy
Auteur(s) :
Azais, Henri [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Queniat, Gurvan [Auteur]
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Bonner, Caroline [Auteur]
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Kerdraon, Olivier [Auteur]
Tardivel, Meryem [Auteur]
Plateforme BioImaging Center Lille - PLBS [BICeL]
Leroux, Bertrand [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Frochot, Céline [Auteur]
Laboratoire Réactions et Génie des Procédés [LRGP]
Betrouni, Nacim [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Collinet, Pierre [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Mordon, Serge [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Queniat, Gurvan [Auteur]
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Bonner, Caroline [Auteur]
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Kerdraon, Olivier [Auteur]
Tardivel, Meryem [Auteur]
Plateforme BioImaging Center Lille - PLBS [BICeL]
Leroux, Bertrand [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Frochot, Céline [Auteur]
Laboratoire Réactions et Génie des Procédés [LRGP]
Betrouni, Nacim [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Collinet, Pierre [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Mordon, Serge [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Titre de la revue :
International Journal of Gynecological Cancer
Pagination :
1/7
Éditeur :
Lippincott, Williams & Wilkins
Date de publication :
2015-08-04
ISSN :
1048-891X
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Cancer
Résumé en anglais : [en]
Objective: Ovarian cancer prognosis remains dire after primary therapy. Recurrence rates are disappointingly high as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease ...
Lire la suite >Objective: Ovarian cancer prognosis remains dire after primary therapy. Recurrence rates are disappointingly high as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease within 5 years. Special attention to undetected peritoneal metastasis and residual tumorous cells during surgery is necessary as they are the main predictive factors of recurrences. Folate receptor [alpha] (FR[alpha]) shows promising prospects in targeting ovarian cancerous cells. Our aim was to determine if the Fischer model described by Rose et al could be used to evaluate folate-targeted therapies in preclinical studies.Methods: NuTu-19 epithelial ovarian cancer cell line was used to induce peritoneal carcinomatosis in female Fischer 344 rats. FR[alpha] expression by NuTu-19 cells was assessed in vitro by immunofluorescence using "Cytospin(R)" protocol. In vitro folate-targeted compound uptake by NuTu-19 cells was evaluated by incubation of FR[alpha]-positive ovarian cancer cell lines (NuTu-19/SKOV-3/OVCAR-3/IGROV-1) with or without (control) a folate-targeted photosensitizer. Intracellular incorporation was assessed by confocal microscopy. Determination of in vivo FR[alpha] tissue expression by several organs of the peritoneal cavity was studied by immunohistochemistry.Results: NuTu-19 cells express FR[alpha] which allows intracellular incorporation of folate-targeted compound by endocytosis. FR[alpha] is expressed in tumor tissue, ovary, and liver. Peritoneum, colon, small intestine, and kidney do not express the receptor.Conclusions: Female Fischer 344 rat is an inexpensive reproducible and efficient preclinical model to study ovarian peritoneal carcinomatosis folate-targeted therapies.Lire moins >
Lire la suite >Objective: Ovarian cancer prognosis remains dire after primary therapy. Recurrence rates are disappointingly high as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease within 5 years. Special attention to undetected peritoneal metastasis and residual tumorous cells during surgery is necessary as they are the main predictive factors of recurrences. Folate receptor [alpha] (FR[alpha]) shows promising prospects in targeting ovarian cancerous cells. Our aim was to determine if the Fischer model described by Rose et al could be used to evaluate folate-targeted therapies in preclinical studies.Methods: NuTu-19 epithelial ovarian cancer cell line was used to induce peritoneal carcinomatosis in female Fischer 344 rats. FR[alpha] expression by NuTu-19 cells was assessed in vitro by immunofluorescence using "Cytospin(R)" protocol. In vitro folate-targeted compound uptake by NuTu-19 cells was evaluated by incubation of FR[alpha]-positive ovarian cancer cell lines (NuTu-19/SKOV-3/OVCAR-3/IGROV-1) with or without (control) a folate-targeted photosensitizer. Intracellular incorporation was assessed by confocal microscopy. Determination of in vivo FR[alpha] tissue expression by several organs of the peritoneal cavity was studied by immunohistochemistry.Results: NuTu-19 cells express FR[alpha] which allows intracellular incorporation of folate-targeted compound by endocytosis. FR[alpha] is expressed in tumor tissue, ovary, and liver. Peritoneum, colon, small intestine, and kidney do not express the receptor.Conclusions: Female Fischer 344 rat is an inexpensive reproducible and efficient preclinical model to study ovarian peritoneal carcinomatosis folate-targeted therapies.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :
Fichiers
- https://hal.archives-ouvertes.fr/hal-01183323/document
- Accès libre
- Accéder au document
- https://hal.archives-ouvertes.fr/hal-01183323/document
- Accès libre
- Accéder au document
- https://hal.archives-ouvertes.fr/hal-01183323/document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- 15.pdf
- Accès libre
- Accéder au document